Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 20262.4.2026 18:32:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / April 2, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that CEO Nathaniel (Nate) T. Bradley will present and exhibit the Company's DataValue®, DataScore®, Data Vault Bank® AI Agent, and patented Information Data Exchange® technologies at XRP Tokyo 2026 on April 7, 2026, at Happo-en in Tokyo, Japan. Bradley's presentation, "Data-Driven RWA Tokenization: Unlocking Japan's Trillion-Yen Opportunity on the XRP Ledger," will demonstrate how Datavault AI's platforms support secure, AI-powered tokenization of real estate, commodities, and other high-value assets in Japan's regulation-friendly market. Japan has emerged as Asia's leading real-world asset tokenization market, with institutional platforms such as Progmat (MUFG-backed) managing approximately ¥440 billion (~$2.8 billion USD) in token
Valsoft Corporation Strengthens Its Retail Software Portfolio with the Acquisition of NedFox2.4.2026 15:00:00 CEST | Press release
MONTRÉAL, QC / ACCESS Newswire / April 2, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Montreal-based company specializing in the acquisition and development of vertical market software businesses, is pleased to announce the acquisition of NedFox, the Netherlands-based software producer of RetailVista, a comprehensive Retail ERP platform designed to support modern retail operations. Headquartered in the Netherlands, NedFox develops and markets RetailVista, an integrated cloud-based Retail ERP solution that enables retailers to manage point-of-sale, inventory, purchasing, financial administration, and reporting within a unified environment. With a strong focus on continuous innovation and customer-driven development, NedFox has built a reputation for delivering reliable, scalable software tailored to the evolving needs of retail businesses. "NedFox has built a robust and highly regarded Retail ERP platform with RetailVista, supported by a passionate team and a strong customer focus,"
Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care2.4.2026 14:10:00 CEST | Press release
Gedeon Richter's Side-by-Side Conference on Advancing Women's Health brought together Healthcare practitioners from 40 countries for a dynamic two-day exchange on March 26-27, making it the largest event of its kind ever organized by the company. BUDAPEST, HU / ACCESS Newswire / April 2, 2026 / Developed in collaboration with internationally recognized experts and grounded in peer-reviewed data, the program provided evidence-based updates on recent advances and innovations across key therapeutic areas, underscoring scientific integrity and evidence-based discussions. Beyond the science, the conference brought into focus how effective communication between healthcare professionals and patients can lead to improved diagnostic accuracy, treatment adherence, and overall patient satisfaction, as emphasized during his keynote lecture by Sukhbir Sony Singh, Full Professor and Chair of the Department of Obstetrics and Gynecology at the University of Ottawa. Day 1 focused on endometriosis and u
U.S. Polo Assn. Supports Division I National Intercollegiate Championship, Showcasing the Future of the Sport of Polo2.4.2026 13:00:00 CEST | Press release
DI Women's and Men's Finals to be Featured in ‘Breakaway: Polo in College' on ESPN WEST PALM BEACH, FLA. / ACCESS Newswire / April 2, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the Division I National Intercollegiate Championship (NIC), held March 19-22, 2026, near Dallas, Texas, at the Prestonwood Polo & Country Club. As the highest level of collegiate polo in the United States, the NIC brings together the nation's top student-athletes to compete for national titles.2026 Division I Women's National Intercollegiate Champions, University of South Carolina - Aiken Polo Team Winifred Branscum, Madison Jordan, and Brianna Jordan; 2026 Division I Men's National Intercollegiate Champions, University of North Texas Polo Team Alec Felhaber, Niklaus Felhaber, Johann Felhaber, Mosiah Gravesande, Sebastian Celis Guerrero Photo Credit: @oanaphoto As a proud supporter of the USPA's Intercollegiate/Interscholastic (I/I) Program,
Datavault AI Inc. (NASDAQ: DVLT) and Demora Foundation Execute Technology Integration Agreement to Power the K-Entertainment & K-Wave Global Platform1.4.2026 17:50:00 CEST | Press release
DVLT × Demora Foundation: Datavault AI's Enterprise AI Stack Deployed as the Data Intelligence & RWA Tokenization Layer for K-Pop, K-Drama, K-Entertainment, and K-Culture IP - Serving 200M+ Hallyu Fans Across 156 Countries Through K2Global's 500+ Korean SMB Network and Three US Innovation K-Wave Cities PHILADELPHIA, PA AND WILMINGTON, DE / ACCESS Newswire / April 1, 2026 / Datavault AI Inc. (NASDAQ:DVLT), an AI-driven data monetization, RWA tokenization, and Web 3.0 infrastructure company, and Demora Foundation, the Delaware-incorporated governing organization of the Demora Chain ecosystem (governed under JP3E Holdings Inc.), today announced the execution of a Technology Integration Agreement establishing Datavault AI as the formal AI data intelligence and RWA tokenization technology partner for the K-Entertainment & K-Wave Global Platform - the integrated K2Global + Demora Foundation ecosystem that converts Korean cultural IP, live entertainment, and K-Wave soft power into institution
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom